Peggs K S
Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Cytotherapy. 2006;8(5):427-36. doi: 10.1080/14653240600851938.
Allogeneic hematopoietic stem cell transplantation is a potentially curative treatment modality for a number of hematologic malignancies, as well as inherited immunodeficiencies and hemoglobinopathies, and may also have a role in selected acquired autoimmune disorders. The complete or near-complete ablation of host immunity and subsequent establishment of donor-derived immunity that is required for successful engraftment and long-term outcomes provide a major obstacle to such transplantation approaches. A delicate balance exists between the need for the reconstituted donor-derived immunity to provide both protection against pathogenic challenges and graft-versus-malignancy activity, and the potentially harmful expansion of alloreactive T-cell clones mediating GvHD. The search for interventions that would allow more rapid and selective reconstitution of beneficial immune specificities continues to be informed by the development of new tools enabling a more precise dissection of the kinetics of reconstituting populations. This review summarizes more recent data on immune reconstitution following allogeneic transplantation in humans.
异基因造血干细胞移植是多种血液系统恶性肿瘤、遗传性免疫缺陷病和血红蛋白病的一种潜在治愈性治疗方式，在某些获得性自身免疫性疾病中也可能发挥作用。成功植入和长期疗效所需的宿主免疫的完全或近乎完全清除以及随后供体来源免疫的建立，为此类移植方法带来了重大障碍。在重建的供体来源免疫既要提供针对病原体挑战的保护又要具备移植物抗恶性肿瘤活性的需求，与介导移植物抗宿主病（GvHD）的同种反应性T细胞克隆的潜在有害扩增之间，存在着微妙的平衡。随着能够更精确剖析重建群体动力学的新工具的开发，寻找能够实现有益免疫特异性更快速、选择性重建的干预措施的工作仍在持续推进。本综述总结了人类异基因移植后免疫重建的最新数据。
